Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 928 for:    stem cells | Studies With Results

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01775774
Recruitment Status : Completed
First Posted : January 25, 2013
Results First Posted : August 14, 2017
Last Update Posted : August 14, 2017
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Massachusetts General Hospital
Stanford University
University of Pittsburgh
University of Minnesota - Clinical and Translational Science Institute
Information provided by (Responsible Party):
Michael A. Matthay, University of California, San Francisco

Tracking Information
First Submitted Date  ICMJE January 18, 2013
First Posted Date  ICMJE January 25, 2013
Results First Submitted Date  ICMJE December 18, 2015
Results First Posted Date  ICMJE August 14, 2017
Last Update Posted Date August 14, 2017
Study Start Date  ICMJE July 2013
Actual Primary Completion Date February 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 2, 2017)
Incidence of Pre-specified Infusion Associated Adverse Events [ Time Frame: 24 hours ]
Any of the following occurring within 6 h of mesenchymal stem-cell infusion:
  • Addition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:
  • Norepinephrine: 10 μg per min
  • Phenylephrine: 100 μg per min
  • Dopamine: 10 μg/kg per min
  • Epinephrine: 0·1 μg/kg per min
  • Hypoxaemia requiring an increase in the fraction of inspired oxygen of ≥0·2 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%
  • New cardiac arrhythmia requiring cardioversion
  • New ventricular tachycardia, ventricular fi brillation, or asystole
  • A clinical scenario consistent with transfusion incompatibility or transfusion-related infection
  • Cardiac arrest or death within 24 h of mesenchymal stem-cell infusion
Original Primary Outcome Measures  ICMJE
 (submitted: January 24, 2013)
Safety [ Time Frame: 7 days ]
Incidence of pre-specified infusion associated events occurring within 6 hours of administration of hMSCs and of unexpected severe adverse events in ARDS patients treated with hMSCs for 7 days.
Change History Complete list of historical versions of study NCT01775774 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 2, 2017)
  • Incidence of Severe Adverse Events (SAEs) [ Time Frame: Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first. ]
    The number of participants with a severe adverse event during the study was assessed.
  • Ventilator Free Days at Study Day 28 [ Time Frame: time of initiating unassisted breathing to day 28 ]
    Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.
  • Duration of Vasopressor Use (Days) [ Time Frame: 28 days ]
    Days on vasopressor to day 28 after study enrollment
  • ICU Free Days to Day 28 [ Time Frame: 28 days after study enrollment ]
  • Hospital Survival to Day 60 [ Time Frame: 60 days after randomization ]
    The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.
  • Mortality at Hospital Discharge [ Time Frame: From study enrollment to Hospital discharge ]
    The number of patients expired at hospital discharge.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 24, 2013)
Safety [ Time Frame: Up to 12 months ]
Unexpected adverse events up to 12 months
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
Official Title  ICMJE A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome
Brief Summary This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.
Detailed Description The primary objective of this study is to assess the safety of intravenous infusion of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) in patients with ARDS.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acute Respiratory Distress Syndrome
Intervention  ICMJE Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
Study Arms  ICMJE Experimental: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
Intervention: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 24, 2013)
9
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 2015
Actual Primary Completion Date February 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:

Acute onset (defined below) of:

  1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP)
  2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph
  3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.

In addition to meeting inclusion criteria, enrollment must occur within 96-hours of first meeting ARDS criteria per the Berlin definition of ARDS.

Exclusion Criteria:

  1. Age less than 18 years
  2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS
  3. Pregnant or breast-feeding
  4. Prisoner
  5. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years
  6. Any other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%
  7. Moderate to severe liver failure (Childs-Pugh Score > 12)
  8. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen
  9. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
  10. Major trauma in the prior 5 days
  11. Lung transplant patient
  12. No consent/inability to obtain consent
  13. Moribund patient not expected to survive 24 hours
  14. WHO Class III or IV pulmonary hypertension
  15. Documented deep venous thrombosis or pulmonary embolism within past 3 months
  16. No arterial line/no intent to place an arterial line
  17. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol
  18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01775774
Other Study ID Numbers  ICMJE ARDS MSC 001
1U01HL108713-01 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Michael A. Matthay, University of California, San Francisco
Study Sponsor  ICMJE Michael A. Matthay
Collaborators  ICMJE
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Massachusetts General Hospital
  • Stanford University
  • University of Pittsburgh
  • University of Minnesota - Clinical and Translational Science Institute
Investigators  ICMJE Not Provided
PRS Account University of California, San Francisco
Verification Date May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP